Purpose: To identify genetic changes that could drive cancer pathogenesis in never and ever smokers with lung adenocarcinoma.
Introduction
The majority of lung cancers are caused by tobacco smoking. However, even in people who have never smoked, lung cancer would rank as the seventh most common cause of cancer death worldwide (1) . In 2000, lung cancer in never smokers accounted in France for 17% cancer deaths in women and 4% in men (2) .
For 4 major genes involved in the pathogenesis of lung cancers, ALK, EGFR, KRAS, and TP53, striking differences in the molecular alterations of these genes have been found in lung cancers in never and ever smokers (3, 4) . Molecular alterations include translocations for ALK or point mutations for EGFR, KRAS, and TP53 (5, 6) . In addition, copy number changes contribute through associated gene deregulation to the malignant phenotype. For instance, MYC is frequently amplified and overexpressed in lung cancer (7) . No study has reported definitive associations between amplifications or deletions and smoking status (8) .
We analyzed the copy number and gene expression profiles of lung adenocarcinomas and related the alterations to smoking status. Having found differences in the tumor profiles, we integrated copy number and gene expression data to identify genetic changes that could drive cancer pathogenesis. The present study differed from previous studies on 2 aspects. First, the number of tumors from never smokers was greater in our study than in previous studies (8, 9) . Second, to control for potential bias, the ever smoker group was constructed by matching ever smokers to never smokers, such that the whole cohort was enriched in never smokers and the group of ever smokers had clinical characteristics (sex, disease stage) identical to never smokers.
Materials and Methods
Detailed information on patients, samples, and methods used in copy number, gene expression, and survival analyses is available as Supplementary Materials and Methods.
Patients and samples
All 165 study patients were treated by surgery for lung adenocarcinoma without prior chemotherapy. Fifty-eight patients received cisplatin-based adjuvant chemotherapy. Never smoking status was defined by a lifetime exposure of less than 100 cigarettes. The tumors were classified according to the tumor-node-metastasis (TNM) system in use at the time of diagnosis (10) . The pathologic diagnoses were reviewed according to current histologic classification for lung carcinoma (11, 12) . Cases for which a doubt about the primary site in the lung remained were excluded. All adenocarcinomas were invasive. A bronchiolo-alveolar component was recorded when a noninvasive lepidic growth was seen adjacent to a component of invasive adenocarcinoma.
This study was part of the Lung Genes (LG) project, which was approved by the Institut National du Cancer review board (Programme National d'Excellence Sp ecialis e Poumon). Informed consent was obtained from patients for the use of their lung surgical samples.
Only cases with an average of tumor cells equal to or above 50% were included. Genomic DNA and RNA were extracted and assessed for integrity and quantity following stringent quality control criteria (cit.ligue-cancer.net).
Genomic DNA analysis
Genomic DNAs were hybridized on Illumina SNP HumanCNV370 chips (Illumina). The GISTIC version 2.0 algorithm (www.broadinstitute.org/cancer/pub/GIS-TIC2) was used to identify significant regions of amplification or deletion. The frequencies of aberrations contributing to significant peak regions were compared using c 2 tests.
Gene expression analysis
Total RNAs were hybridized to Affymetrix Human Genome U133 Plus 2.0 GeneChip (Affymetrix). Unsupervised hierarchical clustering analysis of tumor samples from the LG cohort and normal lung samples from 11 female Asian never smokers (accession number: GSE 19804) was conducted on the most variant probe sets. Differences between sample clusters were tested using the c 2 test. Hypergeometric enrichment for Gene Ontology sets (GeneOntology.org) and MYC target genes (www.myccancergene.org) were calculated with false discovery rate (FDR) correction of P values. Literature Vector Analysis (LitVAn) was used to infer gene cluster functionality with an evaluation of the significance of their scores (litvan.bio.columbia.edu).
Both genomic and gene expression data were deposited in ArrayExpress database (accession number: E-MTAB-923).
ATAD2 relative expression was measured by real-time reverse transcriptase PCR (RT-PCR) using the Hs00204205 TaqMan probe (Applied Biosystems).
Integration of copy number and gene expression data
We used Copy Number and Expression In Cancer (CON-EXIC) to integrate matched copy number (amplifications or deletions) and gene expression data from 80 paired sample (13) .
As described by Akavia and colleagues, CONEXIC is based on the following assumptions: (i) a driver mutation in a "modulator" gene should be associated (correlated) with a group of genes that form a "module" and (ii) copy number aberrations often influence the expression of genes in the module via changes in expression of the modulator.
The CONEXIC learning algorithm consists of 3 key steps:
1. Selection of candidate genes that are recurrently amplified or deleted in tumors. 2. Single Modulator step that creates an initial association between expression of candidate drivers and expression of genes modules. 3. An iterative Network Learning step to improve the initial model.
During the Single Modulator and the Network learning steps, the search is driven by the optimization of a Bayesian scoring function similar to Module Network (14) . For each node, the driver-split combination that achieves the highest score is selected as long as it is verified to be statistically significant. Significance is tested using Lee and colleagues permutation test (15) ; up to 3 top-scoring modulator genes are tried, and if none of them pass the permutations significance test, no more splits are added to the driver tree. In addition to significance testing, nonparametric bootstrap serves to eliminate spurious correlations.
The output is a driver network that divides the expressed genes into modules and associates each module with a driver tree. Each node in the tree is associated with a driver gene (modulator gene) and a threshold expression level (split value) and divides the expression values of the module's members into samples in which the modulator's
Translational Relevance
Our results suggest that the aberrant expression of MYC targets that participate in the program responsible for uncontrolled proliferation may be attributed to ATAD2-deregulated expression. This further suggests that ATAD2 levels may predict the MYC dependency of lung adenocarcinoma, which should be exploited for therapeutic purposes. While MYC has been considered as a frequent and very relevant therapeutic target in lung cancer, specific inhibition of MYC has not been achieved and no MYC inhibitor is currently in the clinic. ATAD2 is worthwhile to investigate as a therapeutic target, which appears feasible given its ATPase activity and its bromodomain.
expression is below the threshold and those in which the modulator's expression is above the threshold. Each side of the split at the first root of the tree (herein designated as the first-order split) can contain further splits (secondary splits) using other modulator/expression threshold pairs.
A detailed description of the selection of candidate genes and of the specified parameters for the Single Modulator and the Network Learning steps as well as a discussion of the significance levels under which modulators were identified are available as Supplementary Information (Supplementary Materials and Methods).
The modules and their modulators were visualized using Genatomy (www.c2b2.columbia.edu/danapeerlab/html/ genatomy.html).
To nominate the module associated with smoking status, we used gene set enrichment analysis (GSEA; ref. 16 ).
For validation, we used the publicly available gene expression data from 68 lung adenocarcinomas (accession number: GSE 12667; ref. 17) and from 391 lung adenocarcinomas (caarraydb.nci.nih.gov, pId ¼ 1015945236141280; ref. 18 ). The linear relationship between a modulator and its associated genes was measured using the Pearson correlation coefficient.
Survival analysis
The univariate overall survival analyses were conducted using the Kaplan-Meier method and log-rank tests. In the multivariate proportional hazard Cox overall survival analysis, ATAD2 expression was studied together with age, sex, and disease stage.
Results
Different frequency of aberrations in significant peak regions between never and ever smokers A total of 121 high-quality genomic profiles were obtained. Frequent aberrations (frequency >25%) included gains on 1p, 1q, 5p, 5q, 6p, 7p, 7q, 8q, 14q, 16p, 17q, 20p, and 20q and losses on 1p, 3p, 4q, 5q, 6q, 8p, 9p, 10q, 12p, 13q, 15q, 17p, and 18q. The GISTIC 2.0 algorithm was applied to identify regions that were significantly amplified or deleted (Fig. 1) . A total of 59 significant peak regions with a frequency of 13% to 84% were identified, including 22 regions that were amplified and 37 regions that were deleted.
The frequency of amplifications or deletions in the 59 significant regions was compared between never and ever smokers. After adjustment for multiple comparisons using Bonferroni method, only 2 regions were differentially amplified or deleted according to smoking status: amplifications were more frequent in ever smokers (83%) compared with never smokers (52%) at 8q24.12 (q-value ¼ 0.02), whereas deletions were more frequent in ever smokers (50%) compared with never smokers (13%) at 4q35.2 (q-value ¼ 0.0006). 
Two groups of tumors with distinctive gene expression clusters and different clinicopathologic annotations
Unsupervised hierarchical clustering of gene expression in 103 high-quality tumor profiles and 11 normal lung samples (GSE19804) revealed 2 groups of tumors (Fig. 2) . The partition was stable as assessed by resampling. The first group of tumors was characterized by the expression of a gene cluster (cluster c) that was common to normal lung samples and mainly absent from tumors in the second group. Two genes clusters (cluster f and cluster i) were overexpressed in the second group of tumors, whereas they were both expressed at low levels in most tumors of the first group and in normal lung samples.
The cluster f was enriched for Gene Ontology (GO) terms "cell cycle process" (q-value ¼ 1.7E-17) and "mitotic cell cycle" (q-value ¼ 1.8E-11) and designated as the "proliferative" cluster. Typical genes in the proliferative cluster encoded cyclins (CCNA2, CCNB1, and CCNE2), the cyclin-dependent kinase CDK6, E2F transcription factors (E2F7, E2F8), and 12 proteins involved in mitosis. The cluster i was enriched for the GO term "extra-cellular matrix" (7.0E-14). Typical genes in cluster i encoded members of the disintegrin and metalloproteinase (ADAM12, ADAMDEC1, ADAMTS5) or matrix metalloproteinase (MMP1, MMP3, MMP11, MMP12, MMP13) families.
Using LitVAn, significant terms associated with the proliferative cluster were "cyclin" and "mitotic" as well as "spindle," reflecting the enrichment for genes participating to the mitotic spindle (BUB1, CENPF, KIF14, KIF15, NDC80, NEK2, NUF2, SKA1, SPC25, TPX2, TTK; genome. ucsc.edu). LitVAn significant terms for cluster i included "invasion," favoring its designation as the "invasive" gene cluster (Supplementary Table S1 ). The first group of tumors whose gene expression resembled normal lung comprised 35 never smokers (74%) and 12 ever smokers, whereas the second group comprised 28 never smokers (50%) and 28 ever smokers (P ¼ 0.01). In the first group, the tumors more frequently presented with a bronchiolo-alveolar component (P ¼ 5E-6) or harbored an EGF receptor (EGFR) mutation (P ¼ 0.0002), whereas in the second group, they more often harbored a KRAS mutation (P ¼ 0.02).
ATAD2 as a likely driver of cell proliferation
Eight-hundred and eighteen genes overlapped significant aberrations less than a third of chromosome length, including 350 genes overlapping 19 amplifications and 468 genes overlapping 34 deletions. Among these genes, 109 genes overlapped the 2 regions that were differentially altered between never and ever smokers. The expression of 175 genes, including 35 that overlapped the 8q24.12 and 4q35.2 smoking status-related aberrations (Table 1) , was significantly altered (P < 0.05) by either their amplification status or deletion status.
Using CONEXIC, we found a model comprising 67 modules that were associated with 31 main modulators (i.e., likely drivers at the first-order split of the regulatory programs) explaining the behavior of 10,001 genes.
We wished to uncover the likely drivers of differentially expressed clusters, which were revealed by the unsupervised analysis of gene expression in the whole cohort. We had 2 collections of gene sets, one provided by the unsupervised analysis in 103 patients (the a to j gene clusters), the other by CONEXIC in 78 patients with paired genomic and gene expression data (the 67 modules). Both collections were determined without the help of clinical or biologic annotations. We thus conducted hypergeometric enrichment analysis to identify which of the gene sets overlapped in the 2 datasets and thus indicate likely drivers of the overlapping clusters in the whole cohort. The proliferative cluster (cluster f in the unsupervised analysis) intersected very significantly (q-value ¼ 2.0E-37) with CONEXIC module 62 (Fig.  3A) . Twenty-eight of 46 genes of cluster f were identified as module 62 genes. The proliferative cluster did not intersect with any other CONEXIC modules. Module 62 genes were enriched in the GO term "cell cycle process" (q-value ¼ 1.2E-87). The main modulator associated with module 62 was ATPase family, AAA domain containing 2 (ATAD2), a gene located at 8q24.12.
A linear relationship between the expression of ATAD2 and the expression of proliferation-related genes in both never and ever smokers
To verify the association between ATAD2 expression and genes in its module, the module 62 regulatory programs identified in the LG cohort were applied to gene expression data from 68 lung adenocarcinomas of the Ding cohort (17) . The profiles of module 62 genes were compared using identical split expression values for the modulators. The relationship between high ATAD2 levels and overexpression of module 62 genes was verified in the Ding cohort (Supplementary Fig. S1A ). When ATAD2 was low, however, the second-order regulatory programs depending on TUBB3 did not classify samples in the Ding cohort as well as in the LG cohort, suggesting that this secondary regulator was not optimally chosen by CONEXIC. We replaced TUBB3 expression by ATAD2 expression, which improved the classification of samples in the Ding cohort (Supplementary Fig. S1B ) without altering substantially the original module 62 profiles in the LG cohort ( Supplementary Fig.  S1C ). These results suggested that ATAD2 expression alone could explain the behavior of module 62 genes across datasets. To enable the confirmation of a linear relationship between ATAD2 and the proliferative cluster (cluster f), Pearson correlation coefficients were calculated in the LG cohort, the Ding cohort, and a third independent cohort of 391 patient (18) . There was a strong dose-response relationship between ATAD2, and the proliferative cluster in every cohort as the expression of genes belonging to the proliferative cluster increased with higher ATAD2 levels in Figure 3 . Integrated analysis of paired copy number and gene expression data in 80 lung adenocarcinomas belonging to the LG cohort. A, CONEXIC analysis. Genatomy module network view of CONEXIC module 62. Each row of the heat map corresponds to the expression of a gene across the 80 samples. Gene names indicated at the right of the heat map are sorted by alphabetical order. Sample names are indicated above the heat map. Samples are ordered according to the regulatory programs found by CONEXIC and shown above sample names. The modulators include ATAD2, TUBB3, SLC25A21, and KCNMB4, wherein ATAD2 increased expression at the first-order split and, at the right, second-order split is associated with increased expression of genes in the module. Yellow dotted lines partition the samples according to split values of the modulators. B to D, analysis of gene expression of the proliferative cluster (cluster f) in the LG cohort according to ATAD2 expression and according to smoking status, 8q24.12 amplification, or MYC expression. Proliferative cluster genes are those included in the final set of genes after processing of LG gene expression data during the CONEXIC procedure. Gene names indicated at the right of the heat map are sorted by alphabetical order. B, samples are sorted in ever (blue) or never smokers (white) and then sorted within each smoking status category into 4 groups of increasing ATAD2 expression levels (from white to red). The 4 ATAD2 groups are sorted using the split values found by CONEXIC in the analysis of the LG cohort. C, samples are sorted according to 8q24.12 amplification, comparing amplification (blue) versus no amplification (white), then within each category into 4 groups of increasing ATAD2 expression levels as above. D, samples are sorted according to increasing MYC expression levels using quartile values as split values (from light to dark blue), then within each category into 4 groups of increasing ATAD2 expression levels as above.
the LG (correlation coefficient 0.85), Ding (correlation coefficient 0.77), and Shedden (correlation coefficient 0.75) cohorts.
In the LG cohort, the expression of the proliferative cluster increased with higher ATAD2 levels in never (correlation coefficient 0.83) and in ever smokers (correlation coefficient 0.87; Fig. 3B) . A similarly strong linear relationship was noted in both the Ding and the Shedden cohorts for never and ever smokers and patients with unknown smoking status ( Table 2 ).
In the LG cohort, the expression of ATAD2 strongly correlated with the expression of the proliferative cluster in every subgroup defined by sex, disease stage, bronchioloalveolar component, EGFR, or KRAS status (Table 2 and Supplementary Fig. S2 ). Although high ATAD2 was less frequent among tumors without 8q24.12 amplification, ATAD2 was differentially expressed and strongly correlated with expression of the proliferative cluster in tumors with or without the amplification (Fig. 3C and Table 2 ).
ATAD2 and module 62 relationships with 8q14.12 amplification and smoking status
On the basis of the array data, ATAD2 expression was associated with 8q24.12 amplification status (P ¼ 1.1E- Table 1 ) and was higher in ever smokers (P ¼ 0.0004). It was neither associated with CDKN2A nor RB1 overlapping deletions. In a subset of 76 patients with available RNA for real-time RT-PCR analysis, ATAD2 expression was increased in ever smokers compared with never smokers (fold change ¼ 1.75, P ¼ 0.02) and in patients with 8q24.12 amplification compared with no amplification (fold change ¼ 2.27, P ¼ 0.001).
As the number of ever smokers was higher in the group of tumors expressing the proliferative cluster f, we tested the association of smoking status with each CONEXIC module using GSEA. The profiles in ever smokers as compared with never smokers were significantly enriched in the module 62 gene set to which the highest enrichment score was given (0.86 for the enrichment score, 1.67 for the normalized enrichment score, 0.02 for the nominal P, and 0.22 for the FDR).
Relationships between ATAD2, MYC, and proliferationrelated genes
Module 62 genes were enriched (q-value ¼ 3.2E-4) for genes of the MYC target database (www.myccancergene. org). Three CONEXIC modules other than module 62 were associated with ATAD2 as their main modulator, one of which was also enriched for MYC targets (q-value ¼ 0.005). Enrichments for the proliferative cluster genes, GO terms containing "cell cycle process" and MYC targets were aligned only for module 62 (Supplementary Table S2 ).
Amplifications of 8q24.12 included both ATAD2 and MYC in every sample save one. Like ATAD2, MYC expression was associated with 8q24.12 amplification (P ¼ 8.0E-5; Table 1 ) and was higher in ever smokers than in never smokers (P ¼ 0.002).
The correlation of the proliferative cluster with MYC (correlation coefficient 0.39) was less strong, however, than with ATAD2 (correlation coefficient 0.85). Remarkably, the correlation of MYC targets in the proliferative cluster was less strong with MYC (correlation coefficient 0.33) than with ATAD2 (correlation coefficient 0.83). Likewise, mitotic spindle genes correlated weakly with MYC, whereas they correlated strongly with ATAD2 (Supplementary Table S3 ). Overexpression of the proliferative cluster occurred in tumors with low MYC and it correlated with ATAD2 (Fig. 3D) . The modest correlation of the proliferative cluster with MYC was verified in both Ding and Shedden cohorts ( Table 2) .
Survival of patients
In the 78 patients from the LG cohort with paired copy number and gene expression array data, the survival rates were 0.75 [95% confidence interval (CI), 0.65-0.88] at 3 years and 0.61 (95% CI, 0.48-0.77) at 4 years for the low ATAD2 group and 0.59 at 3 years (95% CI, 0.43-0.83) and 0.44 (95% CI, 0.28-0.71) at 4 years for the high ATAD2 group (Fig. 4A) . Survival was not significantly different according to ATAD2 expression (P ¼ 0.14). Late disease stage was associated with a shorter survival (P ¼ 0.01). None of the other clinical or biologic variables, including 8q24.12 amplification (P ¼ 0.58) and MYC expression (P ¼ 0.77), was associated with survival.
In the 75 patients who were studied using PCR to measure ATAD2 expression, neither the PCR data (P ¼ 0.41) nor the ATAD2 array data (P ¼ 0.43) were associated with survival.
In the 349 patients from the Shedden cohort, the survival rates were 0.74 (95% CI, 0.68-0.81) at 3 years and 0.65 (95% CI, 0.58-0.73) at 4 years for the low ATAD2 group and 0.58 (95% CI, 0.51-0.66) at 3 years and 0.5 (95% CI, 0.43-0.58) at 4 years for the high ATAD2 group (Fig. 4B) . Survival time was longer in the low ATAD2 group than in the high ATAD2 group (P ¼ 0.002). Late disease stage was strongly associated with shorter survival (P ¼ 1E-16).
Multivariate proportional hazard Cox models were tested to investigate the association of ATAD2 array data with survival and to adjust for age, sex, and disease stage in the 78 patients from the LG cohort and in the 349 patients from the Shedden cohort. In the LG cohort, the best model (likelihood P ¼ 0.008) included ATAD2, age, and disease stage. An older age (HR, 2.18; 95% CI, 1.04-4.55; P ¼ 0.04) and late disease stage (HR, 2.32; 95% CI, 1.17-4. Survival rate Figure 4 . Kaplan-Meier curves of overall survival rates according to ATAD2 levels in the LG cohort, comparing high versus low ATAD2 levels. Shown is the log-rank P value. A, LG cohort. B, Shedden cohort.
were associated with a shorter survival. 
Discussion
Our study reveals that ATAD2 is a likely driver of cell proliferation in lung adenocarcinoma. ATAD2 overexpression both explains the behavior of cell cycle genes and, most likely, results primarily from amplification, thereby connecting proliferation of lung cancer cells to a unique genetic aberration. Furthermore, our results suggest that the oncogene MYC, which is located 4.3 Mb distal to ATAD2 (http:// genome.ucsc.edu/), is involved in that pathway as the ATAD2 associated proliferative signature includes MYC targets involved in cell cycle. Before our study, it was known that ATAD2 is upstream of MYC and that it can exert a role in the proliferation of normal and cancer cells, strongly supporting our conclusion (19) (20) (21) . The present study is the first to provide evidence suggesting that amplified ATAD2 is the main driving force behind MYC contribution to uncontrolled cell proliferation in lung adenocarcinoma. The crucial driving function shown here for ATAD2 may have therapeutic implications. While MYC has been considered as a frequent and very relevant therapeutic target in lung cancer, specific inhibition of MYC has not been achieved and no MYC inhibitor is currently in the clinic. ATAD2 is worthwhile to investigate as a therapeutic target, which appears feasible given its ATPase activity and its bromodomain (22) . Moreover, ATAD2 expression predicts the expression of mitotic spindle genes, whose products participate to a network vulnerable to inhibition of SUMOylation (23) (24) (25) .
A key factor in uncovering the contrasted phenotypes that are summarized by gene clusters in the unsupervised analysis of gene expression is the comparison of normal lung and tumors, many of which were from never smokers. Lung adenocarcinomas in never smokers present typically with a bronchiolo-alveolar component with well-differentiated tumor cells, whereas in ever smokers growth is usually "fully invasive," that is, consists exclusively of invasive component (11, 26) . Consistent with histology, gene expression in the group where never smokers were numerous resembled that of normal lung. In contrast, the group with more ever smokers expressed proliferative or invasive gene clusters.
Most of the frequent aberrations shown in this cohort have been previously reported (8) . However, the frequencies of aberrations in 2 significant regions of amplification or deletion differ according to smoking status. These results raised the question whether the deregulation of genes overlapping differentially altered regions explain the differences in expression profiles between tumors.
To identify driving mutations and the processes they influence, we integrated copy number and gene expression data using the recently developed algorithm CONEXIC (13) . With this approach, the starting list of candidate drivers includes only the genes within or near-significant regions of copy number changes. As a result, CONEXIC would not detect drivers that are typically associated with point mutations.
We identify ATAD2 as a likely driver whose expression explains the behavior of differentially expressed proliferation-related genes. Indeed, an ATAD2-associated module outputted by CONEXIC contained a majority of genes of the proliferative cluster identified in the unsupervised analysis of gene expression, an enrichment very unlikely caused by chance. A strong dose-response relationship between ATAD2 levels and those of genes belonging to the proliferative cluster is shown in the LG cohort and is verified in 2 independent validation cohort (17, 18) . The relationship between ATAD2 and proliferation-related genes is neither affected by smoking status nor smoking status-associated characteristics including KRAS or EGFR mutation.
ATAD2 is correctly associated by CONEXIC with genes that it is known to regulate. ATAD2 has been identified as a cofactor for MYC-dependent transcription by Cir o and colleague (19) . Here, ATAD2-associated genes were significantly enriched in MYC targets. Kalashnikova and colleagues using chromatin immunoprecipitation assays showed that ATAD2 occupies the proximal promoter regions of several key cell-cycle regulators (BUB1, CCNA2, KIF15, MCM10, and TOP2A), which we show linearly related to ATAD2 expression in lung adenocarcinoma (27) .
ATAD2 overlaps the 8q24.12 region which was more frequently amplified in ever smokers. ATAD2 expression was associated with 8q24.12 amplification, suggesting that ATAD2 deregulation occurs primarily through copy number changes. Nevertheless, it was ATAD2 expression and not 8q24.12 amplification that correlated with the expression of proliferation-related genes. Discrepancies between 8q24.12 amplification and ATAD2 overexpression point to additional genetic or epigenetic events contributing to ATAD2 expression. It has been suggested ATAD2 deregulation may be the consequence of the loss of retinoblastoma (RB)-mediated control in a subset of highly aggressive breast cancer (27) . We checked that ATAD2 expression was not associated with deletions targeting the RB pathway.
MYC and ATAD2 are frequently co-amplified in cancers (www.broadinstitute.org/tumorscape), a consistent finding in this cohort. Co-amplification may be selected in tumors as a way to concomitantly overexpress not too far apart cooperating genes. Like ATAD2, MYC was overexpressed in ever smokers, and MYC overexpression was associated with 8q24.12 amplification. Increased expression of MYC targets appears necessary to the association of ATAD2 with cell proliferation as other ATAD2-associated modules that were not enriched in MYC targets were not enriched in proliferation-related genes. As compared with ATAD2, expression of MYC only weakly correlated, however, with expression of the proliferative cluster, including MYC target genes and mitotic spindle genes. These results suggest that ATAD2 levels through MYC activity are more important than MYC levels to drive cell proliferation in lung adenocarcinoma. Assuming that MYC protein levels are roughly equivalent to mRNA levels, it may seem surprising that MYC activity is not directly related to MYC expression. However, using a novel in vivo model of Myc-induced tumorigenesis, Murphy and colleagues reported that low levels of deregulated Myc are competent to drive ectopic proliferation of somatic cells and lung oncogenesis (28) .
High ATAD2 is associated with poor survival of patients with breast cancer (19, 27) . Caron and colleagues reported that high ATAD2 (E. and C. Brambilla, unpublished data) predicts a shorter survival of patients with lung cancer (29) . In the LG cohort, ATAD2 is not significantly associated with survival, although there is a trend when the array data are adjusted for disease stage and age. There is much uncertainty in the results in small groups. In the larger Shedden cohort, high ATAD2 predicts a shorter survival, which is consistent with the reported prognostic value of a cluster of cell proliferation-related gene (18) . The prognostic value of ATAD2 is independent of disease stage in that cohort.
ATAD2 is a co-activator, which can control MYC-dependent transcription (19, 27) . Through MYC and E2F transcription factors, ATAD2 increases the expression of proliferation-related and anti-apoptotic genes in many different types of cancer, including hormone-dependent prostate or breast carcinomas, estrogen receptor-negative breast carcinoma, cervical carcinoma, glioblastoma, osteosarcoma, and non-small cell lung carcinoma (19, 20, 21, 27, 29, 30) . Although these data strongly support that ATAD2 may drive cell proliferation in various cancers, more experiments are needed to investigate the mechanisms by which ATAD2 likely influences the biologic consequences of MYC deregulation in the context of lung cancer cells.
In summary, ATAD2 is identified by a comparative and integrative approach as a likely driver of cell proliferation in lung adenocarcinoma. MYC is co-amplified with ATAD2 and, like ATAD2, is overexpressed in ever smokers. However, it is ATAD2 and not MYC expression that is strongly related to the expression of proliferation-related genes, especially mitotic spindle genes. These results suggest that the aberrant expression of MYC targets that participate in the program responsible for uncontrolled proliferation may be attributed to ATAD2-deregulated expression. This further suggests that ATAD2 levels may predict a MYC dependency of lung adenocarcinoma, which should be exploited as a priority target for therapeutic purposes.
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